Cart
sales@molnova.com
DW71177
CAS No. 2241311-72-6
DW71177( —— )
Catalog No. M37566 CAS No. 2241311-72-6
DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 188 | In Stock |
|
| 10MG | 302 | In Stock |
|
| 25MG | 607 | In Stock |
|
| 50MG | 918 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDW71177
-
NoteResearch use only, not for human use.
-
Brief DescriptionDW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
-
DescriptionDW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241311-72-6
-
Formula Weight384.48
-
Molecular FormulaC20H28N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCCCNC1=NC=2C=C(OC)C=CC2N3C1=NN=C3C)CC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.?
molnova catalog
related products
-
BRD4-BD1-IN-2
BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.
-
BRD4 Inhibitor-20
BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.
-
FHT-1015
FHT-1015 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with potential anticancer activity for the study of cancer and inflammation.
